Weekly TechBio News

May 15, 2025

Welcome back to another free edition of MetaphysicalCells 🪐🛸

How Much Information is in DNA 🧬 ❓ by

“So what would this number be? My guess is that you could reduce the amount of DNA by at least 75 percent, but not by more than 98 percent, meaning the information content is:

12 billion bits
× 2 bits / nucleotide
× (2 to 25 percent)
= 480 million to 6 billion bits
= 60 MB to 750 MB

But in reality, nobody knows. We still have no idea what (if anything) lots of DNA is doing, and we're a long way from fully understanding how much it can be reduced. Probably, no one will know for a long time”.

▶️ Etcembly Limited

On May 13, 2025, Oxford, UK TechBio innovator Etcembly has signed 🎆🎇 a collaboration agreement with DJS Antibodies, part of AbbVie Inc (NYSE: ABBV), to accelerate the discovery of novel antibody therapeutics. This inaugural partnership will leverage EMLy’s deep immune repertoire analysis to identify novel antibodies against an undisclosed G protein-coupled receptor (GPCR) target in autoimmune disease (Techbio Pioneer Etcembly Signs Deal With DJS Antibodies, Part of AbbVie, to Accelerate Antibody Discovery Pipeline).

Etcembly’s flagship AI platform EMLy™ stands as the most advanced immune discovery and engineering technology. By bringing together billions of T-cell receptor (TCR) and antibody sequences with cutting-edge bioinformatics, large language models (LLMs) and structural modeling, EMLy enables the exploration of immune system interactions with targets in unprecedented detail. While HEPTAD is DJS Antibodies’ proprietary antibody discovery technology that delivers unprecedented success rates in the discovery of functional antibodies to GPCRs. It is built on a deep understanding of immunology and antibody induction enabling the discovery of functional antibodies to target 🎯 complex protein targets which have been intractable to drug discovery.

📣 “We’ve already showcased EMLy’s ability to discover and optimize picomolar affinity TCRs in months rather than years. With our expanded capabilities now encompassing antibody discovery and engineering, we are thrilled to partner with DJS Antibodies to address challenging targets and drive faster, smarter development of next-generation biotherapeutics.”
Michelle Teng, CEO of Etcembly

Etcembly (2020) is a company that is improving T-cell receptor immunotherapies with its ML platform, EMLy Co-Pilot (👀 Watch a sneak peek of EMLy Copilot in action, basically a Chat GPT for designing immunotherapy). The platform sifts through complex TCR (T cell receptor) patterns and datasets to discover and identify personalized TCR therapeutic options for patients. EMLy, combines cutting-edge computational technologies with transformative large language models (LLMs) and rich public and proprietary datasets to discover and optimize the next-generation of life-changing immunotherapies.

TCRs constitute one of the most promising classes of emerging therapeutics, although are amongst the most complex facets of immune biology. For this reason, Etcembly is building the world’s largest ML database and unmatched immunology expertise to deliver the safest and most powerful TCR immunotherapies through rapid computer-assisted engineering. EMLy utilizes generative large language models to rapidly predict, design and validate TCR candidates (with deep sequencing). Initially, EMLy scans hundreds of millions of TCR sequences then engineers them to achieve low pM affinity and to eliminate cross-reactivity.

The company’s lead therapeutic programme, ETC-101, is an AI-designed bispecific T cell engager that targets PRAME, an antigen present in many cancers but absent from healthy tissue. Etcembly has advanced ETC-101 to the stage of lead optimization in 11 months, compared with 2+ years for conventional TCR discovery and engineering pipelines.

Just a week ago (May 2025) Etcembly was shortlisted for the Health Tech World's 2025 Drug Development Awards in recognition of its groundbreaking AI immune engineering technology. The awards recognize scientific excellence across all stages of drug discovery, from identifying promising molecular targets to delivering novel drugs that improve patient outcomes. Etcembly’s generative AI platform, EMLy, is right now the world’s leading immune repertoire decoding technology, bringing together millions of antibody and TCR sequences with cutting-edge tools to discover and optimize the next generation of immunotherapeutics with unmatched precision and speed. The other two finalists of the competition are SynaptixBio Ltd and the University of Cincinnati College of Medicine/Cincinnati Children's.

Few words now about Etcembly’s new partner, AbbVie.

AbbVie (NYSE: ABBV) is an American pharmaceutical company headquartered in North Chicago, Illinois. To speed up the pace of drug discovery AbbVie developed the AbbVie R&D Convergence Hub (ARCH), which is an industry-leading analytics platform that helps them connect the dots of data like never before. On top of that, AbbVie has so far established the following AI Drug Discovery collaborations or acquisitions:

🛍️ Iktos makes Makya drug design AI accessible on AWS Marketplace 🛍️

“Iktos has announced it has become an Advanced Technology Partner in the Amazon Web Services Partner Network and that its de novo drug design tool, Makya, is now available on the AWS Marketplace.”

🛍️ Also Wiley Teams Up with AWS to Bring Scientific Content to AI Agents 🛍️

“Wiley, a major academic and scientific publisher, announced a new collaboration with Amazon Web Services (AWS) to launch a generative AI agent for scientific literature search on AWS. The new Wiley literature search agent is available as part of an open source toolkit for healthcare and life sciences agents that has been assembled by AWS.”

▶️ Insitro Inc

AI and ML drug development company Insitro will cut ✂️ 22% of its workforce (about ⬇️ 65 jobs) for a sector struggling to hold its financial footing. Insitro noted how the restructuring would sharpen its focus on key priorities, ensure clinic readiness next year, and keep running into 2027 (4 more biotechs cut staff amid market tumult). Vor Bio, Korro Bio, and Rallybio also revealed plans to lay off chunks of their respective workforces in the latest job cuts.

Insitro (2018, South San Francisco, California) is a drug discovery company that operates an automated lab equipment running on algorithms that use its own in vitro disease models. In particular, Insitro’s predictive models are grounded in human data (genetic, phenotypic and clinical data) using ML. Moreover, they combine patient-derived induced pluripotent stem cells (iPSCs), genome editing, high content cellular phenotyping and ML to build in vitro models of disease. The outcome is an integrated model of disease spanning in vitro cellular systems and in silico ML models—namely an insitro model that allows them to differentiate between cell states at much finer granularity and predict disease-relevant clinical traits.

So far they have found: 🏓 ML-derived imaging and transcriptional phenotypes in genetic epilepsies; 🏓 have revealed distinct phenotypes from the world’s largest collection of familial, sporadic and isogenically engineered cell lines derived from patients with ALS; 🏓 they have built an ML-native datastore containing significant amounts of multimodal high-content human primary data from a wide variety of solid tumors and discovered un/underexplored pathways that are active in a variety of solid tumors; 🏓 and their ML-driven genetic analysis has enabled the identification of multiple genes with strong human evidence of causality for MASLD that are potentially independent of overall adiposity.

On April 1, 2024, the company signed a six-year lease extension with Alexandria Real Estate Equities (ARE) for 143,188 square feet at Alexandria’s life sciences center in South San Francisco.

On October 9, 2024, Insitro announced that has teamed up with Eli Lilly (NYSE: LLY) to help power programs into the clinic, tapping the Big Pharma for an option on technology to deliver siRNA molecules it discovered using its ML platform (AI-powered Insitro taps Lilly to clear path to clinic for siRNA). In particular, the new strategic agreements with Lilly are focused on advancing potential new medicines for metabolic diseases, including metabolic dysfunction-associated steatotic liver disease (MASLD), based on targets identified by Insitro using the company’s AI/ML-based platform.

🖇️ Under the first two agreements, Insitro has an option to in-license proprietary, clinical stage, ternary N-acetylgalactosamine (GalNAc) delivery technology from Lilly that it will combine with two different small interfering ribonucleic acid (siRNA) molecules discovered and developed by Insitro, each specifically directed toward a different target in the liver.
🖇️ Under the third agreement, Insitro and Lilly will collaborate to discover and develop an antibody for a third novel target for metabolic disease. As part of the collaboration, the companies will work together on the early preclinical development activities until development candidate nomination, when insitro will be responsible for all remaining development and commercialization.

✂️ Also FDA Cuts Staff and Plans AI Integration in Drug Development by June:

✂️ The FDA plans to introduce generative AI across all centers by the end of June, following substantial workforce reductions that began last month. This means that tasks previously performed by humans will be entrusted to AI.

▶️ Algorae Pharmaceutical Ltd

The Australasian biotechnology company Algorae Pharmaceuticals Limited (ASX code: 1AI) announced that it has entered into an agreement 🤝 with the Victorian Centre for Functional Genomics at Peter MacCallum Cancer Centre to validate AI predicted drug synergies through high-throughput screening. The study will evaluate 24 drug candidates (21 wholly AI generated) using VCFG’s advanced screening platform, which includes proprietary high-throughput technologies and synergy assessment methodologies (Algorae Pharmaceuticals partners with Peter Mac for AI-driven drug synergy screening).

The company ‘s development of AlgoraeOS Version 2.0 is progressing rapidly and includes now expanded data integration and advanced ML enhancements. Algorae is collaborating on the development with experts from the AI Institute at the University of New South Wales and receiving economic support from the Data61 specialist arm of Australia’s CSIRO national science agency (Algorae Pharmaceuticals strengthens drug pipeline as AlgoraeOS Version 2.0 development continues). Version 2.0 aims to increase the platform’s predictive precision and support broader application across multiple disease classes, including the generation of novel and patentable fixed-dose combination therapies.

Algorae Pharmaceuticals (ASX: 1AI) launched (on September 25, 2024) the Version 1.0 of its biopharmaceutical platform AlgoraeOS after development 🏗️ 🚧 at the University of New South Wales. The AlgoraeOS platform aggregates medical and scientific data on over 5,000 known drugs and molecules in over 150 human cell types. The platform uses AI systems to predict fixed-dose combination (FDC) drugs that the company says it will either take to clinical trials itself or do so in collaboration with partners, potentially big pharma (Algorae Pharmaceuticals launched AI-powered platform to generate novel drug candidates).

AlgoraeOS or Algorae Operating System is a closed-loop platform, to evaluate drugs and molecules for repositioning and combining into novel drug candidates aimed at patient cohorts experiencing significant unmet medical need. Moreover, the platform will interpret pre-clinical, clinical, chemical and biological data sets at an enormous scale to provide predictive insights into Algorae’s pipeline of prospective drug candidates.

💱 Biotech firm Metis plans Hong Kong IPO💱

➡️ Hangzhou-based Metis Pharmaceuticals is considering a Hong Kong IPO to raise up to USD 200M, according to sources. The AI-driven drug discovery firm has raised USD 300M to date and counts CICC Capital and HongShan among its key investors.

➡️ Metis Pharmaceuticals Ltd (2020, China) is a biotechnology company that aims to address unmet medical needs by applying AI, ML and quantum simulation to drug delivery and drug discovery, and achieve optimal therapies across a broad spectrum of diseases with its unique interdisciplinary core technology platforms (AiLNP, AiRNA and AiTEM).

METiS has developed a portfolio of over 10 drugs, including small molecule and RNA drugs.
In 2022, METiS Therapeutics emerged with $86M for 2022 clinic entry, push into gene therapy.
On April 06, 2022, METiS Therapeutics announced that it has completed two consecutive rounds of financing totaling $150M.
On May 18, 2022, METiS announced officially joining the Roche Accelerator with the goal to tap into Roche’s (SWX: ROG) global scientific expertise (METiS Joins the Roche Accelerator).

▶️ Cadence Design Systems, Inc

Cadence (Nasdaq: CDNS) just announced a major expansion of its Cadence^® Millennium^™ Enterprise Platform with the introduction of the new Millennium M2000 Supercomputer featuring NVIDIA Blackwell systems, which delivers AI-accelerated simulation at unprecedented speed and scale across engineering and drug design workloads (Cadence Unveils Millennium M2000 Supercomputer with NVIDIA Blackwell Systems to Transform AI-Driven Silicon, Systems and Drug Design).

The new supercomputer integrates Cadence’s industry-leading solvers with NVIDIA HGX B200 systems, NVIDIA RTX PRO 6000 Blackwell Server Edition GPUs and NVIDIA CUDA-X libraries and solver software. This powerful combination delivers dramatic reductions in simulation run times and up to 80X higher performance versus CPU-based systems for electronic design automation (EDA), system design and analysis (SDA), and drug discovery applications.
The supercomputer provides a tightly co-optimized hardware-software stack that enables breakthrough performance with up to 20X lower power across multiple disciplines, accelerating the build-out of AI infrastructure, advancing physical AI machine design and pushing the frontiers of drug design.

▶️ Inductive Bio Inc

Inductive Bio raised $25M 💰 in Series A financing led by Obvious Ventures with participation from Andreessen Horowitz (a16z) Bio + Health, Lux Capital, S32, Character, and Amino Collective, alongside angel investors including Oren Etzioni, Jeff Hammerbacher, Malay Gandhi, and Jakob Uszkoreit (Inductive Bio Raises $25M Series A to Transform Small Molecule Drug Discovery with Industry-Wide AI Platform). The funding will power Inductive's Compass platform, which predicts a drug's ADMET properties before a molecule is synthesized, guiding chemists towards molecules with the highest likelihood of success.

Inductive Bio emerged from stealth in 2023, unveiling an ML platform to accelerate compound optimization in drug discovery. They have the most comprehensive and best-curated commercially available dataset for small-molecule ADMET prediction. Inductive's proprietary training sets are carefully normalized to account for the heterogeneity in real-world data and are continuously growing to fill in gaps for specific chemotypes and assays. Their models can be used confidently for decision making in real-world heterogeneous ADMET data.

On July 29, 2024, Inductive Bio announced the publication in the ACS Medicinal Chemistry Letters of the approach and findings from their recent collaboration with Nested Therapeutics, that highlights the pivotal role of ML models for ADMET (Absorption, Distribution, Metabolism, Excretion, and Toxicity) alongside computational potency predictions for prioritizing synthetic targets and enhancing design quality (Inductive Bio Announces Publication of Successful Drug Optimization Collaboration with Nested Therapeutics). By combining Inductive's ADMET foundation models (which leverage state-of-the-art deep learning methods trained on proprietary ADMET datasets) with Nested's computational platform for predicting the potency of compounds in cryptic pockets the two companies allowed Nested to reduce the number of compounds synthesized and accelerate the lead optimization process. Nested Therapeutics, a Cambridge-based VC-backed biotech company that emerged from stealth in 2022 with $125M to fight cancer, is leveraging computational engineering, biology and a handful of niche fields in life science to map mutational clusters onto the structural proteome, find “druggable pockets” and design new drugs for those pockets.

🆕 New Kids on the Block 🆕

➡️ Intrepid Labs raises $7 million to expand AI-driven formulation platform

➡️ Stately Bio: $12 Million Closed For Developing Regenerative Medicines With Cellular Imaging Platform

➡️ Twist Bioscience Spins Out DNA Data Storage as Independent Company (with $155 million in backing)

➡️ ReportAId Raises €2.2M in Pre-Seed Funding

▶️ Peptone Ltd

Peptone has a new partnership 🧑‍🤝‍🧑 with Evotec to accelerate and scale the creation of small molecule IDP-targeted treatments across diverse therapeutic areas. Through the collaboration, Peptone will harness Evotec's drug discovery toolbox—encompassing deep domain expertise in oncology and immunology, extensive assay development know-how, and state-of-the-art screening capabilities—to seamlessly integrate with its pioneering, physics-based approach to understanding IDP structural dynamics (Peptone Establishes Strategic Partnership with Evotec to Selectively Target Intrinsically Disordered Proteins (IDPs) and Advance Small-Molecule Therapeutics at Scale).

Peptone—founded in 2018 and born out of 30 years of academic research at the universities of Cambridge, Oxford, ETH Zurich and Groningen—is a translational biophysics company focused on drugging Intrinsically Disordered Proteins (IDRs). The focal point of their protein therapeutics platform (Oppenheimer) is an intersection of physics, molecular biology, and next generation supercomputing.

Many intrinsically disordered 🧐 proteins (Troponin T, Alpha-synuclein, p53) are directly implicated in human pathologies and are very difficult to target with drugs. For this reason, proprietary NMR experiments (Nuclear Magnetic Resonance spectroscopy) coupled with HDX-MS (Hydrogen deuterium exchange mass spectrometry) as well as other experiments are all used to generate ambiguous restraints for modeling of proteins ensembles of IDRs targets.

Peptone’s proprietary Molecular Dynamics engine utilizes the experimental restraints to simulate non-canonical behavior of the disordered targets and identify the most plausible drugging sites. Their ML methods generate compact but diverse libraries of high quality protein binders against the best ranking spatial disordered epitopes. Finally, their advanced biophysical laboratory performs lead selection and end to end testing. A data driven decision is made if the binder selection process requires more iterations.

▶️ Eli Lilly and Company (NYSE: LLY) and AI Drug Discovery

The American multinational pharmaceutical company Eli Lilly and Company, doing business as Lilly, is licensing rights to an AI-Discovered Phase 1-ready antibody (ATLX-1282) that startup ✴️ Alchemab developed for amyotrophic lateral sclerosis and other neurodegenerative disorders (Eli Lilly Turns to Alchemab to Add Another AI-Discovered ALS Drug Prospect). Lilly’s pipeline also has ALS drug candidates from previous deals with QurAlis (QurAlis: Neuro Pioneers on a Quest to Cure) and Verge Genomics.

Cambridge, England-based Alchemab by using ML and LLMs to read and process an antibody’s amino acid sequence is focusing on the discovery and development of naturally occurring protective antibodies for hard to treat diseases. Alchemab’s technology identifies antibodies associated with resilience to diseases in areas such as neurodegeneration, immunology, oncology, and healthy aging.

Apart from the recent deal with Alchemab worth up to $415M including upfront and downstream plus royalties on top (and the collaboration with Insitro mentioned previously), Eli Lilly and Company (NYSE: LLY) has just signed a research and licensing agreement with ✴️ Creyon Bio worth up to $1 billion to develop RNA-targeted therapies using AI and quantum chemistry, according to Drug Target Review (Eli Lilly Bets on Quantum Chemistry in $1 Billion RNA Drug Deal With Creyon). The agreement, announced on May 12, 2025, gives Lilly access to Creyon’s AI-based platform for designing RNA-targeted therapies. The deal includes $13M in upfront cash and equity and sets the stage for milestone payments exceeding $1 billion if the collaboration results in commercial therapies.

The US-based startup Creyon Bio specializes in oligonucleotide-based medicines (OBMs) by combining biology, genomics, pharmacology, biophysics and chemistry with ML/AI. Creyon’s advanced platform works by identifying the design rules and engineering principles for OBMs, including modalities ranging from single-stranded antisense oligonucleotides (ASOs) that reduce gene expression levels or change splicing events to small interfering RNA (siRNA), to DNA and RNA editing systems, to even targeting aptamers. Then it builds accurate predictive models of safety and efficacy.

Further to this research and licensing agreement with Creyon Bio, on September 5, 2024, Eli Lilly jumped deeper into AI with $409M ✴️ Genetic Leap deal, by using Genetic’s RNA-targeted AI platform to generate genetic drug candidates against selected targets. More specifically, Lilly will pick targets in high-priority areas and Genetic Leap will find oligonucleotide drugs against the targets. On March 14, 2024, Eli Lilly-backed ✴️ Zephyr AI (with AI algorithms to build tools and products for the healthcare industry) that secured $111M for precision medicine tech. On January 7, 2024, ✴️ Isomorphic inked deals with Eli Lilly and Novartis for drug discovery. On Dec. 21, 2023, ✴️ Fauna Bio, a biotechnology company improving human health by leveraging animal genomics, announced a multi-year agreement with Eli Lilly to apply Fauna's Convergence™ AI platform to support preclinical drug discovery efforts in obesity. The two teams will collaborate to identify multiple drug targets. And on May 30, 2023, Eli Lilly and ✴️ XtalPi inked a $250M deal for AI-powered drug discovery. XtalPi’s drug discovery abilities stem from its Inclusive Digital Drug Discovery and Development, or ID4, platform, which is equipped with hundreds of AI algorithms—encompassing ML, DL and natural language processing approaches—and biochemical, cellular, pharmacodynamic and pharmacokinetic testing tech.

💰 Eli Lilly and venture capital firm Andreessen Horowitz (a16z) just joined forces to create a unique new fund dubbed the Biotech Ecosystem Venture Fund, backed by $500M of Lilly’s capital (Eli Lilly, Andreessen Horowitz link up on $500M biotech venture fund).

The alliance combines a16z’s biotech venture prowess with Lilly’s R&D expertise to “foster a technology ecosystem of ambitious bio + health entrepreneurs and innovators”. Lilly and a16z have operated in the same circles for years and have invested in some of the same firms, according to a STAT News report and executives from both companies birthed the idea for the fund at a 2023 meet-up, during which they found common ground in a long-term vision of how AI technology can shape both organizations.

▶️ Anthropic PBC

Anthropic's AI for Science program is a new initiative designed to accelerate scientific research and discovery through access to its API. This program will provide free API credits to support researchers working on high-impact scientific projects, with a particular focus on biology and life sciences applications (Introducing Anthropic's AI for Science Program).

At Anthropic, they believe that AI has the potential to significantly accelerate scientific progress. Advanced AI reasoning and language capabilities can help researchers analyze complex scientific data, generate hypotheses, design experiments, and communicate findings more effectively. By reducing the time and resources needed for scientific discovery, they can help address some of humanity's most pressing challenges.

The AI for Science program will offer significant API credits to qualified researchers who will be selected based on their contributions to science, the potential impact of their proposed research, and AI’s ability to meaningfully accelerate their work.

🏮 Lantern ’s Investigational Drug-Candidate, LP-184 (or STAR-001)🏮

Lantern Pharma Secures FDA Clearance for Planned Phase 1b/2 Trial of LP-184 in Biomarker-Defined, Treatment-Resistant NSCLC Patients with High Unmet Clinical Need

▶️ Japan Tobacco Inc (NIHON TABAKO SANGYO KABUSHIKI KAISHA)

Shionogi & Co. said it plans to acquire 🛒 Japan Tobacco Inc. (JT) subsidiaries Torii Pharmaceutical Co. and Akros Pharma Inc. for ¥160 billion (US$1.1 billion) to expand its global R&D business. The two companies have been negotiating since early 2024, and the deal is structured such that a tender offer will begin on May 8 and end on June 18 with an offer price of ¥6,350 per share to buy at least 11.89% of the minority stake (Shionogi to acquire Japan Tobacco pharma companies for $1.1B).

Moreover on April 28, 2025, the pharmaceutical division of Japan Tobacco and D-Wave Quantum Inc. (NYSE: QBTS), a leader in quantum computing systems, software and services, have announced the successful 💯 completion of a proof-of-concept project applying quantum computing and AI to drug discovery. The project demonstrated that a hybrid quantum-classical system outperformed classical methods in generating potential drug compounds (D-Wave Quantum (NYSE: QBTS) and Japan Tobacco Complete Quantum AI Project Designed to Improve Drug Discovery Outcomes).

The project used D-Wave’s annealing quantum computer to enhance the training of large language models (“LLMs”) for chemical structure generation. LLMs were integrated into JT’s drug discovery process to explore chemical space and propose novel molecular structures. The hybrid quantum approach produced a higher proportion of valid, drug-like molecules compared to classical-only models. The generated compounds displayed a higher quantitative estimate of “drug-likeness” than the molecules in the training data or those produced through classical LLM training. This suggests that annealing quantum computing may help optimize low-energy molecular configurations more effectively than conventional computing alone.

The two, JT and D-Wave, started their collaboration back on October 1, 2024 (D-Wave And Japan Tobacco Collaborated On Quantum AI-Driven Drug Discovery To Accelerate Pharmaceutical Innovation) when D-Wave and JT’s pharmaceutical division announced a joint proof-of-concept project to use quantum computing and AI for drug discovery, specifically in the “Quantum AI-driven Drug Discovery” process.

D-Wave Quantum Inc is a leader in the development and delivery of quantum computing systems, software and services, and is the world’s first commercial supplier of quantum computers—and the only company building both annealing quantum computers and gate-model quantum computers. D-Wave’s technology has been used by some of the world’s most advanced organizations including Mastercard, Deloitte, Davidson Technologies, ArcelorMittal, Siemens Healthineers, Unisys, NEC Corporation, Pattison Food Group Ltd., DENSO, Lockheed Martin, Forschungszentrum Jülich, University of Southern California, and Los Alamos National Laboratory.

🏅 IPA's LENSai™ Platform Delivers X-Ray--Level Epitope Mapping Ins 🏅

💠 ImmunoPrecise Antibodies Ltd. (IPA) delivers groundbreaking epitope mapping results with its LENSai™ platform.

💠 The AI-powered platform achieves x-ray-level precision in hours, comparable to traditional gold-standard methods.

💠 LENSai™ reduces costly and time-consuming lab work, offering a scalable approach to antibody discovery.

▶️ OpenAI Inc

Microsoft MSFT +2.40% ▲ backed OpenAI and FDA are exploring the potential of integrating AI into drug evaluation processes. A small team from OpenAI has been meeting with the FDA to discuss the dynamics of a project 🆕 called “cderGPT.” CDER is short for Center for Drug Evaluation and Research, the body responsible for regulating over-the-counter and prescription drugs in the U.S. (OpenAI and FDA Explore AI Integration in Drug Evaluations). The cderGPT project aims to streamline the drug approval process, potentially making it more efficient and accurate. While still in the early stages, this collaboration could herald a new era in how medications are assessed and approved, blending healthcare and AI innovation in an unprecedented fashion (FDA and OpenAI Chat about AI in Drug Evaluations under the CDERGPT Project).

News 📰

🔸Countdown to SLAS Europe: Minos Biosciences SA

🔸Sapient Launches DynamiQ™ as Its Next-Generation Data Insights Engine for Drug Discovery and Development

🔸Newly Launched DCx Biotherapeutics In-Licenses Discovery Platforms and Retains Talent and Infrastructure From Repare Therapeutics to Accelerate Development of Multi-Modal

🔸FutureHouse Unveils Superintelligent AI Agents to Revolutionize Scientific Discovery

Until next week 🐞

MetaphysicalCells